Eli Lilly invests $1.8 bln in Ireland sites to scale up Alzheimer's, obesity drug production
London: Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.
The investments are part of Lilly's ongoing commitent to expand production, especially for its top-selling diabetes and obesity drugs, Mounjaro and Zepbound, respectively.
The company has committed over $20 billion since 2020 to build and expand its manufacturing facilities in the U.S. and Europe.
The company said it has invested roughly $800 million in its new facility in Kinsale, Ireland, which began manufacturing Lilly's obesity and diabetes medicines last year. Demand for Zepbound has outpaced supply for most of this year.
The rest of the investment will go towards expanding the drugmaker's facility in Limerick, Ireland, which will focus on producing active biologic ingredients for certain drugs, including the Alzheimer's treatment.
Lilly's drug for Alzheimer's received U.S. approval in July and is currently under review with the European and UK health regulators.
Danish rival Novo Nordisk has also invested billions in manufacturing to ramp up supply of its popular weight-loss drug Wegovy, including a $11 billion deal to take over three sites from contract manufacturer Catalent.
In the U.S., Lilly quickly built a market share of around 40 per cent since launching Zepbound in December. Analysts believe that as Lilly increases its manufacturing capacity, the market could be roughly split 50-50 between Lilly and Novo Nordisk by the end of this year.
Some analysts forecast the market for new weight-loss drugs could reach $150 billion annually by the early 2030s. (Reporting by Bhanvi Satija in Bengaluru; Editing by Janane Venkatraman)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.